Abstract
Devising therapies for neurodegenerative diseases remains a major challenge due to the complex etiology, prolonged disease course and the paucity of validated targets. These factors make it difficult to model neurodegenerative diseases in a manner amenable to large-scale screening. However, recent developments in automation, combinatorial chemistry and high-throughput phenotypic assays have presented new opportunities for discovering small molecule therapeutics for neurodegenerative diseases. This review focuses on novel in vitro and phenotypic screens for Huntingtons disease and a few other neurodegenerative diseases. The lessons learned from these screens and the potential of the small molecules identified as therapeutic leads are discussed.
Keywords: Drug discovery, huntington's disease, models, polyglutamine disease, screening, therapy, Amyotrophic Lateral Sclerosis, ALS, SMER's, small molecule enhancers of rapamy, synuclein, FGF-2, CNTF, brain derived growth factor, BDNF, Fluorescence Resonance Energy transfer, FRET, Y-27632, spinocerebellar ataxia-1, SCA-1, su-peroxide dismutase, SOD, caffeic acid phenylethyl ester, CAPE
Current Molecular Pharmacology
Title: Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders
Volume: 3
Author(s): Hemant Varma
Affiliation:
Keywords: Drug discovery, huntington's disease, models, polyglutamine disease, screening, therapy, Amyotrophic Lateral Sclerosis, ALS, SMER's, small molecule enhancers of rapamy, synuclein, FGF-2, CNTF, brain derived growth factor, BDNF, Fluorescence Resonance Energy transfer, FRET, Y-27632, spinocerebellar ataxia-1, SCA-1, su-peroxide dismutase, SOD, caffeic acid phenylethyl ester, CAPE
Abstract: Devising therapies for neurodegenerative diseases remains a major challenge due to the complex etiology, prolonged disease course and the paucity of validated targets. These factors make it difficult to model neurodegenerative diseases in a manner amenable to large-scale screening. However, recent developments in automation, combinatorial chemistry and high-throughput phenotypic assays have presented new opportunities for discovering small molecule therapeutics for neurodegenerative diseases. This review focuses on novel in vitro and phenotypic screens for Huntingtons disease and a few other neurodegenerative diseases. The lessons learned from these screens and the potential of the small molecules identified as therapeutic leads are discussed.
Export Options
About this article
Cite this article as:
Varma Hemant, Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders, Current Molecular Pharmacology 2010; 3 (3) . https://dx.doi.org/10.2174/1874467211003030164
DOI https://dx.doi.org/10.2174/1874467211003030164 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Imbalance and Anxiety Disorders
Current Neuropharmacology Cyclin-Dependent Kinase 5 (Cdk5): A Potential Therapeutic Target for the Treatment of Neurodegenerative Diseases and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer’s Disease
Current Alzheimer Research Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology Heat Shock Proteins as Suppressors of Accumulation of Toxic Prefibrillar Intermediates and Misfolded Proteins in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design The Neurotrophins and Their Role in Alzheimers Disease
Current Neuropharmacology Retraction Notice: Potential Application of Venom Proteins in Designing of Medicines for Treating Human Neurodegenerative Disorders
Protein & Peptide Letters Autophagy in Invertebrates: Insights Into Development, Regeneration and Body Remodeling
Current Pharmaceutical Design <i>Arctium Lappa</i> and Management of Liver Functions to Detoxify the Bloodstream
The Natural Products Journal Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain
Current Topics in Medicinal Chemistry From Chemical Drug to Immunotherapy: New Approaches for the Treatment of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Experimental Models of Discovery: Prediction and Protection must Proceed “Hand-in-Hand”
Current Neurovascular Research An Update on Prion Biology and Proteomics
Current Proteomics 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design